Low-molecular-weight heparin for initial treatment of venous thromboembolism.
Brewer
Dan
D
Department of Family Medicine, University of Tennessee, Knoxville 37920, USA. dbrewer2@utk.edu
D000208:Acute Disease; D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016527:Drug Costs / Q000706:statistics & numerical data; D019317:Evidence-Based Medicine; D005260:Female; D005268:Femoral Vein; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D012449:Safety; D013923:Thromboembolism / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000175:diagnosis / Q000188:drug therapy*
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight